Slide 1: Six-month financial report (1 Dec 2020 – 31 May 2021)
Global virtual care provider within the telerehabilitation sector Six-month financial report (1 Dec 2020 – 31 May 2021) Webcast call presentation July 28th 10:00 CEST
Slide 2: Forward-looking statement
Forward-looking statement This presentation contains certain forward-looking statements and opinions. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for example, contain wording such as “beli
Slide 3: Agenda
Agenda Introduction Q2 Highlights Physitrack at a glance Business update Henrik Molin CEO & co-founder Financial results What’s next – market outlook Q&A Charlotte Goodwin CFO 3
Slide 4: Introduction
+> Physitrack a Introduction
Slide 5: Introduction to the presenters and the management team of Physitrack
Introduction to the presenters and the management team of Physitrack Tech-native management team with strong track-record of digital value creation Henrik Molin Nathan Skwortsow Charlotte Goodwin Andrew Knox Chief Executive Officer CTO / Chief Software Architect and Designer Chief Financial Officer
Slide 6: Q2 Highlights
Q2 Highlights Strong revenue growth on an overall and proforma basis H1 35% proforma revenue H1 revenue growth (vs prior year) growth driven by all three + 184% total companies +37% proforma 65% revenue growth in Physitrack Q2 revenue growth (vs prior year) 34% proforma revenue growth in + 127% tota
Slide 7: Q2 Highlights
Q2 Highlights Significant operational progress and IPO milestone Acquisitions IPO Notable wins Continued focus on EBITDA Successfully completed an initial Circle BMI Healthcare (UK) expansion in Physiotools, public offering on the Nasdaq First CBI Health (Canada) integration and the acceleration Nor
Slide 8: Physitrack at a glance – Who we are
Physitrack at a glance – Who we are Physitrack is a global remote physical therapy SaaS provider for remote patient engagement B2B virtual care SaaS High Growth - Multibillion addressable • Pure play SaaS (90%) High Profitability market with strong • SaaS enabled virtual care philosophy digitalisati
Slide 9: Physitrack at a glance – Where we operate
Physitrack at a glance – Where we operate Proven and cost-efficient expansion model to achieve a truly global footprint whilst maintaining high profitability Foothold markets Near term focus geographies for future expansion Spanish speaking Latin & South America English & French speaking Africa Near
Slide 10: Physitrack at a glance – What we do
Physitrack at a glance – What we do A technology enabler and a virtual care provider in the telerehabilitation market SaaS offering Telerehabilitation market 360 care Patients Patients Healthcare Healthcare Provider Technology Provider Technology Technology Technology / enabled SaaS SaaS SaaS and vi
Slide 11: Business update
+> Physitrack a Business update
Slide 12: IPO – A warm welcome to the public markets
IPO – A warm welcome to the public markets On 18 June 2021 Physitrack PLC successfully completed an initial public offering “IPO” on the Nasdaq First North Premier Growth Market, trading under the ticket “PTRK” 5,031,250 newly issued shares were issued for an offer price of SEK 40, raising additiona
Slide 13: M&A Program – Integration and acceleration of recent acquisitions
M&A Program – Integration and acceleration of recent acquisitions Product enhancement Product enhancement Providing Physitrack with additional content, functions and Enhancing clinical offering with Physitrack technology instructions in multiple languages to support further Market e growth and highe
Slide 14: Financial results
+> Physitrack a Financial results
Slide 15: Strong revenue growth – Beating 12-month growth targets
Strong revenue growth – Beating 12-month growth targets 3,500,000 2,000,000 1,800,000 3,000,000 21% 1,600,000 2,500,000 184% 1,400,000 1,200,000 127% Euro 2,000,000 Euro 1,000,000 37% 1,500,000 800,000 1,000,000 600,000 400,000 500,000 200,000 - - H1 2019/20 (ACTUAL) H1 2019/20 (PROFORMA) H1 2020/21
Slide 16: EBITDA – Stable growth excluding non-recurring costs
EBITDA – Stable growth excluding non-recurring costs 1,200,000 1,000,000 61% €0.3M €1.1M 800,000 ADJUSTED Euro EBITDA Margin 600,000 34% €0.7M €0.8M 400,000 ADJUSTED EBITDA Margin 60% 200,000 - H1 2019/20 EBITDA H1 2020/21 EBITDA Non comparable Costs H1 2020/21 Adjusted EBITDA 16
Slide 17: CASH – Reinvestments in development of SaaS platform and to pursue acquisition strategy
CASH – Reinvestments in development of SaaS platform and to pursue acquisition strategy H1 2020/21 H1 2019/20 FY 2019/20 (Unaudited) (Unaudited) (audited) Adjusted EBITDA 1,125 699 1,629 Working capital & fx (35) 54 428 Movement in loans 66 (34) (3) Purchase of intangibles (569) (449) (978) Interest
Slide 18: BALANCE SHEET – Continued strong position
BALANCE SHEET – Continued strong position 31 May 2021 31 May 2020 30 November 2020 Goodwill, intangibles and PPE 10,463 1,488 7,711 Cash and cash equivalents 995 272 1,254 Borrowings (2,046) - (1,737) Trade and other receivables 877 156 543 Trade and other payables (1,287) (694) (1,251) Deferred rev
Slide 19: What’s next – market outlook
What’s next – market outlook 19
Slide 20: Executing a well-defined growth plan combining organic and inorganic initiatives
Executing a well-defined growth plan combining organic and inorganic initiatives Planning to build a global powerhouse in the remote physical care space through well-defined, tangible organic and inorganic growth objectives 3 M&A initiative 2 Continue on the strong M&A traction following the success
Slide 21: Financial goals – What we aim for
Financial goals – What we aim for Financial goals are aligned with the Physitrack DNA – a strong top-line growth combined with continued high profit margins Top-line growth Profit margins Value creation / distribution Physitrack aims to achieve annual Physitrack targets an EBITDA Physitrack aims to
Slide 22: +> Physitrack a
+> Physitrack a